New theobromine derivatives inhibiting VEGFR-2: design, synthesis, antiproliferative, docking and molecular dynamics simulations.

Background: VEGFR-2 is one of the most effective targets in cancer treatment. Aim: The design and semi-synthesis of new theobromine derivatives as potential VEGFR-2 inhibitors. Methods: In vitro and in silico evaluation of the synthesized compounds. Results: Compound 5b demonstrated excellent antiproliferative and VEGFR-2 inhibitory effects with significant apoptotic activity. It modulated the immune response by increasing IL-2 and reducing TNF-α levels. Docking and molecular dynamics simulations revealed the compound's binding affinity with VEGFR-2. Lastly, computational absorption, distribution, metabolism, excretion and toxicity studies indicated the high potential of compound 5b for drug development. Conclusion: Compound 5b could be a promising anticancer agent targeting VEGFR-2.

[1]  Sai-Yang Zhang,et al.  Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy. , 2023, Bioorganic chemistry.

[2]  Ibrahim M. Ibrahim,et al.  A New Anticancer Semisynthetic Theobromine Derivative Targeting EGFR Protein: CADDD Study , 2023, Life.

[3]  Ibrahim M. Ibrahim,et al.  A New Theobromine-Based EGFRWT and EGFRT790M Inhibitor and Apoptosis Inducer: Design, Semi-Synthesis, Docking, DFT, MD Simulations, and In Vitro Studies , 2022, Processes.

[4]  Ibrahim M. Ibrahim,et al.  (E)-N-(3-(1-(2-(4-(2,2,2-Trifluoroacetamido)benzoyl)hydrazono)ethyl)phenyl)nicotinamide: A Novel Pyridine Derivative for Inhibiting Vascular Endothelial Growth Factor Receptor-2: Synthesis, Computational, and Anticancer Studies , 2022, Molecules.

[5]  Ibrahim M. Ibrahim,et al.  In silico, in vitro VEGFR-2 inhibition, and anticancer activity of a 3-(hydrazonomethyl)naphthalene-2-ol derivative , 2022, Journal of biomolecular structure & dynamics.

[6]  Wagdy M. Eldehna,et al.  Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2,4-diones targeting VEGFR-2 and apoptosis pathway , 2022, PloS one.

[7]  Ibrahim M. Ibrahim,et al.  New Anticancer Theobromine Derivative Targeting EGFRWT and EGFRT790M: Design, Semi-Synthesis, In Silico, and In Vitro Anticancer Studies , 2022, Molecules.

[8]  Wagdy M. Eldehna,et al.  Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies , 2022, Journal of enzyme inhibition and medicinal chemistry.

[9]  Wagdy M. Eldehna,et al.  New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies , 2022, Journal of enzyme inhibition and medicinal chemistry.

[10]  I. Eissa,et al.  A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease , 2022, International journal of molecular sciences.

[11]  Ibrahim M. Ibrahim,et al.  The Assessment of Anticancer and VEGFR-2 Inhibitory Activities of a New 1H-Indole Derivative: In Silico and In Vitro Approaches , 2022, Processes.

[12]  Wagdy M. Eldehna,et al.  Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies , 2022, Journal of enzyme inhibition and medicinal chemistry.

[13]  Ibrahim M. Ibrahim,et al.  Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects , 2022, Molecules.

[14]  S. M. Abou-Seri,et al.  Multi-Step In Silico Discovery of Natural Drugs against COVID-19 Targeting Main Protease , 2022, International journal of molecular sciences.

[15]  Wagdy M. Eldehna,et al.  Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies , 2022, Journal of enzyme inhibition and medicinal chemistry.

[16]  Wael A Alanazi,et al.  Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies. , 2021, Bioorganic & medicinal chemistry.

[17]  D. Dou,et al.  Traditional ancient Egyptian medicine: A review , 2021, Saudi journal of biological sciences.

[18]  M. Elsohly,et al.  Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation. , 2021, Bioorganic chemistry.

[19]  K. Abouzid,et al.  Discovery of potent thieno[2,3-d]pyrimidine VEGFR-2 inhibitors: Design, synthesis and enzyme inhibitory evaluation supported by molecular dynamics simulations. , 2021, Bioorganic chemistry.

[20]  T. Farghaly,et al.  An updated patent review of VEGFR-2 inhibitors (2017-present) , 2021, Expert opinion on therapeutic patents.

[21]  H. Alkahtani,et al.  New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation. , 2021, Bioorganic chemistry.

[22]  C. Liang,et al.  Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study , 2021, Investigational New Drugs.

[23]  M. Alanazi,et al.  New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis. , 2021, Bioorganic chemistry.

[24]  M. Alanazi,et al.  Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as anticancer agents and apoptosis inducers , 2021, Journal of enzyme inhibition and medicinal chemistry.

[25]  G. Simone,et al.  Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role , 2020, Frontiers in Cell and Developmental Biology.

[26]  A. Hamed,et al.  Antitumor properties of certain spirooxindoles towards hepatocellular carcinoma endowed with antioxidant activity , 2020, Journal of enzyme inhibition and medicinal chemistry.

[27]  A. Metwaly,et al.  Black Ginseng and Its Saponins: Preparation, Phytochemistry and Pharmacological Effects , 2019, Molecules.

[28]  Zaina T. Al-Salama,et al.  Lenvatinib: A Review in Hepatocellular Carcinoma , 2019, Drugs.

[29]  Adriano D Andricopulo,et al.  ADMET modeling approaches in drug discovery. , 2019, Drug discovery today.

[30]  Ghada S. Hassan,et al.  Synthesis and in vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents , 2019, Journal of enzyme inhibition and medicinal chemistry.

[31]  el-Sayed Akool,et al.  Vitamin E inhibits cyclosporin A‐induced CTGF and TIMP‐1 expression by repressing ROS‐mediated activation of TGF‐&bgr;/Smad signaling pathway in rat liver , 2018, International immunopharmacology.

[32]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[33]  F. Hamada,et al.  Functional characterization of &agr;7 nicotinic acetylcholine and NMDA receptor signaling in SH‐SY5Y neuroblastoma cells in an ERK phosphorylation assay , 2018, European journal of pharmacology.

[34]  L. Rashed,et al.  Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: synthesis, in vitro biological evaluation, and QSAR studies , 2018, Journal of enzyme inhibition and medicinal chemistry.

[35]  Lei Shi,et al.  VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016) , 2017, Expert opinion on therapeutic patents.

[36]  W. Glanzner,et al.  Guaraná a Caffeine-Rich Food Increases Oxaliplatin Sensitivity of Colorectal HT-29 Cells by Apoptosis Pathway Modulation. , 2016, Anti-cancer agents in medicinal chemistry.

[37]  Linghong Guo,et al.  Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis , 2016, Oncotarget.

[38]  P. Norman.  Orphan drug approvals of 2014: Europe and the United States , 2015 .

[39]  L. Scott.  Lenvatinib: First Global Approval , 2015, Drugs.

[40]  R. Kaiser,et al.  Nintedanib: from discovery to the clinic. , 2015, Journal of medicinal chemistry.

[41]  N. Sugimoto,et al.  Theobromine, the Primary Methylxanthine Found in Theobroma cacao, Prevents Malignant Glioblastoma Proliferation by Negatively Regulating Phosphodiesterase-4, Extracellular Signal-regulated Kinase, Akt/mammalian Target of Rapamycin Kinase, and Nuclear Factor-Kappa B , 2014, Nutrition and cancer.

[42]  Jianping Chen,et al.  Dietary Compound Isoliquiritigenin Inhibits Breast Cancer Neoangiogenesis via VEGF/VEGFR-2 Signaling Pathway , 2013, PloS one.

[43]  Jeong Heo,et al.  Sorafenib in liver cancer , 2012, Expert opinion on pharmacotherapy.

[44]  Kyungik Lee,et al.  Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. , 2010, European journal of medicinal chemistry.

[45]  Carlos Caldas,et al.  Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer , 2008, BMC Cancer.

[46]  N. Mounier,et al.  VEGF and VEGFR‐1 are coexpressed by epithelial and stromal cells of renal cell carcinoma , 2008, Cancer.

[47]  K. K. Lo,et al.  Luminescent biological probes derived from ruthenium(II) estradiol polypyridine complexes. , 2008, Inorganic chemistry.

[48]  F. Balkwill.  TNF-α in promotion and progression of cancer , 2006, Cancer and Metastasis Reviews.

[49]  L. Ellis,et al.  Chemotherapeutic drugs—more really is not better , 2000, Nature Medicine.

[50]  M. Lenardo,et al.  Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. , 2000, Journal of cell science.

[51]  T. McDonnell,et al.  Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) , 1991, Nature.

[52]  F. Denizot,et al.  Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. , 1986, Journal of immunological methods.

[53]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[54]  K. Syrigos,et al.  Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. , 2009, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[55]  B. Chabner,et al.  Chemotherapy and the war on cancer , 2005, Nature Reviews Cancer.